PPD Will Retain Discovery, Development Business Units For The Near Term
This article was originally published in The Pink Sheet Daily
Executive Summary
PPD plans to maintain its dual structure of providing discovery sciences and development services, at least for the near term, CEO Fred Eshelman said Dec. 14
You may also be interested in...
PPD Comprehensive Review Will Examine Resource Allocation
Each division of the CRO will submit a report by the end of July on how to achieve “consistent operating excellence.” CEO Eshelman says changes could be significant or “little tweaks.”
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar